→ Bristol-Myers Squibb vet Caroline Loew has traded an R&D strategy and planning role for the top job at Glympse Bio. After a 20-year career in drug development, with stints at Merck and PhRMA, Loew will now lead the Arch-backed startup in advancing its in vivo disease-monitoring activity sensors.
→ Kaleido Biosciences has scooped Katharine Knobil from GlaxoSmithKline to become its CMO and head up R&D. Founded by Flagship Pioneering in 2015 and boosted by a $101 million mega-round this year, the biotech is developing a pipeline of microbiome-based therapies that Knobil is tasked with steering into Phase II in 2019.
→ Thomas Cannell has brought fellow pharma vet Dennis Kim to his team at Sesen Bio as he steers the newly renamed company through a Phase III trial for the bladder cancer treatment Vicinium (VB4-845). Between Ipsen, Spectrum, Novartis, Biogen and Amgen, the new CMO has been involved in the approval and commercialization of more than 10 products in oncology and immunology, the company says.
→ Gene therapy developer Prevail Therapeutics is shaking up its C-suite for the new year. Brett Kaplan, a managing director at Evercore, is joining as CFO while Celgene vet Emily Minkow gets a promotion to chief business officer from EVP of BD and strategy.
→ As Eiger BioPharmaceuticals $EIGR rallies for a potential pivot into commercial stage, it’s recruited seasoned financial exec Sri Ryali to its leadership. Most recently at Aimmune, where he helped lead an IPO, Ryali’s previous work experience spans Jazz, Onyx and Amgen. He replaces James Welch as CFO.
→ In conjunction with an organizational overhaul that involves cutting a quarter of its staff, MiMedx is also restructuring its C-suite. Chris Cashman is out as the struggling biotech eliminates the chief commercial officer post that he occupied. And then there’s the string of promotions: Mark Landy to chief strategy officer, David Mason to chief medical officer (replacing Donald Ferrerolf, who’s retiring); and John Harris to SVP, marketing and business development.
→ Building on decades of experience in neurological drug development — featuring CMO stints at Acorda and Flex Pharma — Thomas Wessel has taken up a new challenge to lead Swiss biotech Asceneuron’s expansion into the US as its CMO. He will oversee regulatory and clinical development for dementia treatment ASN120290 from the company’s new offices in Cambridge, MA.
→ On the verge of starting Phase III trials for rezafungin, Cidara Therapeutics $CDTX has tapped former Goldman Sachs managing director James Levine as CFO. Also joining the company: Jessica Oien, general counsel and secretary.
→ After 30 years launching and marketing drugs for the likes of Celgene, J&J and Bristol-Myers Squibb, Mark Kreston is taking his commercial chops Knopp Biosciences. As chief commercial officer, he is tasked with devising a global strategy for the company’s treatments for inflammatory and neurological diseases, some of which are poised for Phase II and III studies.
→ Two execs on Celgene’s CAR-T team have jumped to Omeros. Daniel Kirby has been named VP and head of commercial, while Justin McCue will become VP of chemistry, manufacturing and controls, with responsibilities over all of Omeros’ programs ranging from eye therapy to blood clot treatment.
→ Eyeing an entry into the clinic next year, Relay Therapeutics has hired Mary Mader from Eli Lilly to be VP of chemistry and Verastem’s Mahesh Padval as SVP of pharmaceutical drug development.
→ William Westlin is the new EVP of R&D at eGenesis, leading the xenotransplantation research and product development work for the George Church spinout. He previously held similar roles at Nimbus Therapeutics and Avila Therapeutics, but harvesting animal organs for human use will be a new field for him.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.Free Subscription